English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Alzheimer’s disease (AD) is the most common cause of dementia. Aβ 1–42 , Aβ 1–40 , total tau, and hyperphosphorylated tau have been reported to be suitable biomarkers in the diagnosis of AD. Additionally, transthyretin has been suggested as a biomarker since it has been shown to inhibit Aβ aggregation and the formation of senile plaques. Aggregates of Aβ 1–42 are an important hallmark of the pathogenesis of AD. Patients with AD show significantly lower levels of transthyretin in the cerebrospinal fluid (CSF) compared with aging controls or patients with other kinds of dementia. Furthermore, some data indicate that transthyretin levels reflect disease severity in AD. In conclusion, recent work demonstrates the potential of transthyretin as an additional biomarker in the neurochemical differential diagnosis of AD.

Transthyretin Cerebospinal Fluid Levels in Alzheimer’s Disease—Is This a Biomarker for Disease Severity?